Cost-utility analysis of antihypertensive medications in Nigeria: A decision analysis

Cost Effectiveness and Resource Allocation

Volumn 11, Issue 1, 2013, Pages

  Ekwunife, Obinna Ikechukwu ^a   Okafor, Charles E ^a   Ezenduka, Charles C ^a   Udeogaranya, Patrick O ^a  

^a UNIVERSITY OF NIGERIA   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; HUMAN; HYPERTENSION; MONTE CARLO METHOD; NIGERIA; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; QUANTITATIVE ANALYSIS;

EID: 84872593351     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-11-2     Document Type: Article

References (22)

1. Aguwa CN. Therapeutic Basis of Clinical Pharmacy in the Tropics 2004, 102-136. 3.
2. Chobian AV, Bakris JL, Black HR, Cushman WC, Green LA, Izzo JL, Jones WD, Materson BJ, Oparil S, Wright JT, Roccella EJ. National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003, 42:1206-1252. 10.1161/01.HYP.0000107251.49515.c2, 14656957.
3. World Health Organisation Adherence to long-term therapies Evidence for Action [Online]. 2003 [Cited 2008 August 22]; Available from: URL: http://whqlibdoc.who.int/publications/2003/9241545992.pdf Accessed 2 August 2011, World Health Organisation.
4. Ekwunife OI, Aguwa CN. A Meta Analysis of Prevalence of Rate of Hypertension in Nigerian Populations. J Publ Health Epidemiol 2011, 13:604-607.
5. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009, Art. No.: CD001841(Issue 3):CD001841.pub2.
6. Yusuff KB, Balogun OB. Pattern of drug utilization among hypertensives in a Nigerian teaching hospital. Pharmacoepidemiol Drug Saf 2005, 14:69-74. 10.1002/pds.1035, 15508134.
7. Lopez AD, Salomon J, Ahmad O, Murray CJL. Life tables for 191 countries: data, methods and results (GPE discussion Paper No. 9) 2000, Geneva: World Health Organization.
8. Ekwunife OI, Aguwa CN, Adibe MO, Barikpaoar E, Onwuka CJ. Health state utilities of a population of Nigerian hypertensive patients. BMC Res Note 2011, 12(4):528.
9. Brindle P, May M, Gill P, Cappuccio F, D'Agostino R, Fischbacher C, Ebrahim S. Primary prevention of cardiovascular disease: a web-based risk score for seven British black and minority ethnic groups. Heart 2006, 92(11):1592-1602.
10. Whitworth JA, World Health Organization International Society of Hypertension Writing Group 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003, 21(11):983-1992. World Health Organization International Society of Hypertension Writing Group.
11. Akpa MR, Agomouh DI, Alasia DD. Lipid profile of health adult Nigerians in Port Harcourt, Nigeria. Niger J Med 2006, 15(2):137-140.
12. Briggs A, Claxton K, Sculpher M. Decision modeling for health economic evaluation 2006, New York: Oxford University Press Inc.
13. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL. Making choices in health: WHO guide to cost-effectiveness analysis 2003, Geneva: World Health Organization.
14. Nigerian Health Insurance Scheme NHIS Healthcare Providers Service Price List 2005, http://dhmlnigeria.com/downloads/NHISdrugs_pricelist_2011.pdf Accessed16 July 2011, Nigerian Health Insurance Scheme.
15. Trading Economics Power Purchasing Parity conversion factor (GDP) to market exchange rate ratio in Nigeria 2010, URL: http://www.tradingeconomics.com/nigeria/ppp-conversion-factor-gdp-to-market-exchange-rate-ratio-wb-data.html Accessed 15 July 2011, Trading Economics.
16. CBN Data and Statistics Monthly Average Exchange Rates of the Naira (Naira Per Unit of Foreign Currency) - 2010 (Interbank Foreign Exchange Market - IFEM) 2011, URL: http://www.cenbank.org/rates/exrate.asp?year=2010&month=1, CBN Data and Statistics.
17. World Health Organization International Drug Price Indicator Guide 2010, http://apps.who.int/medicinedocs/en/m/abstract/Js18714en/ Accessed 15 July 2011, World Health Organization.
18. Robberstad B, Hemed Y, Norheim OF. Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country - the case of Tanzania. Cost Effectiveness and Resource Allocation 2007, 5:3. 10.1186/1478-7547-5-3, 1808049, 17316431.
19. Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans D, et al. Making Choice in Health: WHO Guide to Cost-effectiveness Analysis 2003, Geneva: World Health Organisation.
20. Nordmann AJ. Cost-effectiveness of Routine Echocardiography in Hypertensive Patients starting Antihypertensive Drug Therapy 2001, http://tspace.library.utoronto.ca/bitstream/1807/15428/1/MQ58821.pdf Accessed 15 December, 2012.
21. The Sixth Report of the Joint National Committee on Prevention Detection, Evaluation and Treatment of High Blood Pressure 1997, http://www.nhlbi.nih.gov/guidelines/archives/jnc6/jnc6_archive.pdf Accessed 15 December, 2012, The Sixth Report of the Joint National Committee on Prevention.
22. Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce IN, Sculpher MJ. The cost-effectiveness of etanercept and infliximab for the treatment. Rheumatology 2007, 46(11):1729-1735. 10.1093/rheumatology/kem221, 17956918.